Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2022

31-01-2022 | Positron Emission Tomography | Review Article

Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond

Authors: Mengting Li, Muhsin H. Younis, Yongxue Zhang, Weibo Cai, Xiaoli Lan

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2022

Login to get access

Abstract

Fibroblast activation protein (FAP) is a type II membrane-bound glycoprotein which is overexpressed in cancer-associated fibroblasts and activated fibroblasts at wound healing/inflammatory sites. Since the first clinical application of quinoline-based FAP ligands in 2018, FAP inhibitor (FAPI)-based PET imaging and radiotherapy have been investigated for a wide variety of diseases, both cancerous and non-cancerous. As a consequence, promising strides have been made in particular to improve the understanding of FAPI-based PET imaging and the potential value of FAPI-based tumor radiotherapy. Herein, we present a comprehensive review of radiolabeled FAPI, including their clinical translation, in order to clarify the current and potential future role of this class of molecules in nuclear medicine. In particular, this review underlines the value of FAPI radiopharmaceuticals in the diagnosis or therapy of tumors or benign conditions. However, limitations in present studies have hampered a precise evaluation of FAPI radiopharmaceuticals. Despite this, it will likely be worthwhile to further explore the clinical value of FAPI in diagnosis and therapy through better-designed and larger-population clinical trials in the future.
Literature
1.
2.
3.
Radzina M, Tirane M, Roznere L, Zemniece L, Dronka L, Kalnina M, et al. Accuracy of (68)Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer. Am J Nucl Med Mol Imaging. 2020;10:106–18.PubMedPubMedCentral
4.
5.
6.
7.
8.
9.
Lamprecht S, Sigal-Batikoff I, Shany S, Abu-Freha N, Ling E, Delinasios GJ, et al. Teaming up for trouble: cancer cells, transforming growth factor-beta1 signaling and the epigenetic corruption of stromal naive fibroblasts. Cancers (Basel). 2018;10. https://​doi.​org/​10.​3390/​cancers10030061.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154–66. https://​doi.​org/​10.​1158/​2326-6066.CrossRefPubMed
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
Zhao L, Pang Y, Zheng H, Han C, Gu J, Sun L, et al. Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:3606–17. https://​doi.​org/​10.​1007/​s00259-021-05336-w.CrossRefPubMed
41.
42.
43.
44.
Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost. 2003;89:561–72.CrossRef
45.
46.
47.
48.
49.
Chen YP CA, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma; 2019.
50.
51.
52.
53.
54.
55.
56.
57.
58.
D Jiang X Chen Z You H Wang X Zhang X Li et al 2021 Comparison of [(68) Ga]Ga-FAPI-04 and [(18)F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study Eur J Nucl Med Mol Imaging https://​doi.​org/​10.​1007/​s00259-021-05441-w
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
Y Pang L Zhao Q Shang T Meng L Zhao L Feng et al 2021 Positron emission tomography and computed tomography with [(68)Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer Eur J Nucl Med Mol Imaging https://​doi.​org/​10.​1007/​s00259-021-05576-w
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. https://​doi.​org/​10.​1089/​thy.​2015.​0020.CrossRefPubMedPubMedCentral
90.
van Dijk D, Plukker JT, Phan HT, Muller Kobold AC, van der Horst-Schrivers AN, Jansen L, et al. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin. Thyroid. 2013;23:1003–9. https://​doi.​org/​10.​1089/​thy.​2012.​0498.CrossRefPubMed
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
Ballal S, Yadav MP, Kramer V, Moon ES, Roesch F, Tripathi M, et al. A theranostic approach of [(68)Ga]Ga-DOTA.SA.FAPi PET/CT-guided [(177)Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:942–4. https://​doi.​org/​10.​1007/​s00259-020-04990-w.
143.
144.
145.
146.
147.
148.
149.
Barreira da Silva R, Laird ME, Yatim N, Fiette L, Ingersoll MA, Albert ML. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol. 2015; 16: 850–8. https://​doi.​org/​10.​1038/​ni.​3201.
150.
151.
152.
153.
Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R. Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [(18)F]F-FDG in oncology: a systematic review. Int J Mol Sci. 2021;22. https://​doi.​org/​10.​3390/​ijms222011192.
154.
155.
156.
CE Mona MR Benz F Hikmat TR Grogan K Luckerath A Razmaria et al 2021 Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study J Nucl Med https://​doi.​org/​10.​2967/​jnumed.​121.​262426
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
Metadata
Title
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond
Authors
Mengting Li
Muhsin H. Younis
Yongxue Zhang
Weibo Cai
Xiaoli Lan
Publication date
31-01-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05706-y

Other articles of this Issue 8/2022

European Journal of Nuclear Medicine and Molecular Imaging 8/2022 Go to the issue

Original Article

Effects of MRI protocols on brain FDG uptake in simultaneous PET/MR imaging

Editorial

State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956–2022)

Original Article

Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma

Original Article

The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study

Original Article

Short-time total-body dynamic PET imaging performance in quantifying the kinetic metrics of 18F-FDG in healthy volunteers

Original Article

[68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT